Benzinga - by Priya Nigam, Benzinga Staff Writer.
TransMedics Group Inc (NASDAQ:TMDX) shares were climbing in early trading on Tuesday.
The clinical trials for the company's Organ Care Systems for the heart, lung and liver have shown strong data, which is expected to continue to drive adoption, according to Stephens.
The TransMedics Analyst: George Sellers initiated coverage of TransMedics with an Overweight rating and price target of $151.
The TransMedics Thesis: The current waiting list for heart, lung and liver transplants represents the near-term expansion opportunity, which equates to $920 million, Sellers said in an initiation note.
Check out other analyst stock ratings.
"Longer-term, if the market utilization rate increases to TMDX’s rates and every new waitlist patient receives a transplant, then the annual opportunity is $1.5 bil. (vs. ~$1.1 bil. in 2023) growing low-single digits annually," the analyst wrote.
The kidney transplant market represents an additional market expansion opportunity, as its volume is 6x the combined heart, lung, and liver transplant volume, he added.
"We believe TMDX has significant runway to inflect to positive cash flow while also investing in the continued growth of the business," Sellers further stated.
TMDX Price Action: Shares of TransMedics had risen by 0.34% to $134.09 at the time of publication on Tuesday.
Read Next: Intel Shares Rise In Pre-Market As Nvidia, AMD Crack After CPU Maker Announces New AI Chip To Take On Rivals
Photo: Shutterstock
Latest Ratings for TMDX
| Feb 2022 | Morgan Stanley | Maintains | Equal-Weight | |
| Jan 2022 | Morgan Stanley | Maintains | Equal-Weight | |
| May 2021 | Morgan Stanley | Maintains | Equal-Weight |
View the Latest Analyst Ratings
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.